These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20938371)

  • 1. Platelet aggregation pathway.
    Sangkuhl K; Shuldiner AR; Klein TE; Altman RB
    Pharmacogenet Genomics; 2011 Aug; 21(8):516-21. PubMed ID: 20938371
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel pathway.
    Sangkuhl K; Klein TE; Altman RB
    Pharmacogenet Genomics; 2010 Jul; 20(7):463-5. PubMed ID: 20440227
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
    Gurbel PA; Tantry US; Shuldiner AR
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.
    Fontana P; James R; Barazer I; Berdagué P; Schved JF; Rebsamen M; Vuilleumier N; Reny JL
    J Thromb Haemost; 2011 Aug; 9(8):1664-6. PubMed ID: 21692977
    [No Abstract]   [Full Text] [Related]  

  • 8. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.
    Fefer P; Matetzky S
    Thromb Haemost; 2011 Aug; 106(2):203-10. PubMed ID: 21792462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV
    Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic variability in the efficacy of clopidogrel].
    Kristensen KE; Rasmussen HB; Hansen PR
    Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
    Gratsianskiĭ NA
    Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
    Ford NF
    J Clin Pharmacol; 2009 May; 49(5):506-12. PubMed ID: 19246723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
    Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
    Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
    Furuta T; Iwaki T; Umemura K
    Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacogenomics of clopidogrel.
    Levitt MR; Osbun JW; Kim LJ
    World Neurosurg; 2012; 77(3-4):406-7. PubMed ID: 22366366
    [No Abstract]   [Full Text] [Related]  

  • 18. Personalised antiplatelet therapy: are we ready for prime time? Data from China.
    Li J; Huo Y
    EuroIntervention; 2013 Jul; 9(3):296-8. PubMed ID: 23872644
    [No Abstract]   [Full Text] [Related]  

  • 19. Can we override clopidogrel resistance?
    Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
    Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
    [No Abstract]   [Full Text] [Related]  

  • 20. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
    Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.